Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ATTRACTION-3: Nivolumab versus chemotherapy in advanced oesophageal squamous cell carcinoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 29.09.19
Views: 646

Prof Byoung Chul Cho - Yonsei University, Seoul, South Korea

Prof Byoung Chul Cho speaks to ecancer at ESMO 2019 in Barcelona about the phase III ATTRACTION-3 study comparing nivolumab with chemotherapy in patients with advanced oesophageal squamous cell carcinoma (ESCC).

He explains that for patients with ESCC who have progressed on platinum based combination chemotherapy there is virtually no option in the second line setting.

He reports that the study demonstrated that nivolumab showed a superior efficacy with manageable toxicities compared to chemotherapy.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

SIOG metastatic renal cell carcinoma

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation